TFR2 and breast carcinoma: Experimentally, knocking down TFR1, TFR2, ACO1, HSPA9, and PLOD1 in the breast cancer cell line MDA-MB-231 resulted in a decrease in the expression level of MEMO1 by 40–60% (Figure 3C), but, as expected, no significant effect in the melanoma cell line A-375 was observed (Figure 3D).